Gemfibrozil, stretching arms beyond lipid lowering
- 1 April 2009
- journal article
- review article
- Published by Taylor & Francis in Immunopharmacology and Immunotoxicology
- Vol. 31 (3) , 339-351
- https://doi.org/10.1080/08923970902785253
Abstract
Gemfibrozil is long known for its ability to reduce the level of triglycerides in the blood circulation and to decrease the risk of hyperlipidemia. However, a number of recent studies reveal that apart from its lipid-lowering effects, gemfibrozil can also regulate many other signaling pathways responsible for inflammation, switching of T-helper cells, cell-to-cell contact, migration, and oxidative stress. In this review, we have made an honest attempt to analyze various biological activities of gemfibrozil and associated mechanisms that may help to consider this drug for different human disorders as primary or adjunct therapy.Keywords
This publication has 105 references indexed in Scilit:
- PPAR Alpha Regulation of the Immune Response and Autoimmune EncephalomyelitisPPAR Research, 2008
- Myelin Basic Protein-primed T Cells Induce Neurotrophins in Glial Cells via α5β3 IntegrinJournal of Biological Chemistry, 2007
- Gemfibrozil Ameliorates Relapsing-Remitting Experimental Autoimmune Encephalomyelitis Independent of Peroxisome Proliferator-Activated Receptor-αMolecular Pharmacology, 2007
- Peroxisome proliferator‐activated receptor‐α agonist fenofibrate regulates IL‐12 family cytokine expression in the CNS: relevance to multiple sclerosisJournal of Neurochemistry, 2007
- Modulation of PPAR activity via phosphorylationPublished by Elsevier ,2007
- Anti-atherogenic properties of fibrates may be largely due to their anti-inflammatory effectsMedical Hypotheses, 2006
- Induction of Glial Fibrillary Acidic Protein Expression in Astrocytes by Nitric OxideJournal of Neuroscience, 2006
- PPARα activation abolishes LDL-stimulated IL-8 production via AP-1 deactivation in human aortic smooth muscle cellsBiochemical and Biophysical Research Communications, 2004
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patientsNeurochemical Research, 1985